| 2022 | Efficacy and safety of atezolizumab, in combination with etoposide and carboplatin regimen, in the first-line treatment of extensive-stage small-cell lung cancer: a single-center experience | CANCER IMMUNOLOGY IMMUNOTHERAPY |
| 2022 | Disproportional enrichment of FoxP3(+)CD4(+) regulatory T cells shapes a suppressive tumourmicroenvironment in head and neck squamous cell carcinoma
| CLINICAL AND TRANSLATIONAL MEDICINE |
| 2022 | Lymphocyte dynamics during and after chemo-radiation correlate to dose and outcome in stage III NSCLC patients undergoing maintenance immunotherapy | RADIOTHERAPY AND ONCOLOGY |
| 2022 | The Development of AXL Inhibitors in Lung Cancer: Recent Progress and Challenges
| FRONTIERS IN ONCOLOGY |
| 2022 | Molecular landscape of osimertinib resistance in patients and patient-derived preclinical models
| THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY |
| 2022 | Predicting treatment outcomes using 18 F-FDG PET biomarkers in patients with non-small-cell lung cancer receiving chemoimmunotherapy
| THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY |
| 2021 | Nephrotoxicity of cancer therapeutic drugs: Focusing on novel agents
| KIDNEY RESEARCH AND CLINICAL PRACTICE |
| 2021 | Overexpression of poliovirus receptor is associated with poor prognosis in head and neck squamous cell carcinoma patients | JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY |
| 2021 | Real-world outcomes of anti-PD1 antibodies in platinum-refractory, PD-L1-positive recurrent and/or metastatic non-small cell lung cancer, and its potential practical predictors: first report from Korean Cancer Study Group LU19-05 | JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY |
| 2021 | Clinical decision support algorithm based on machine learning to assess the clinical response to anti-programmed death-1 therapy in patients with non-small-cell lung cancer | EUROPEAN JOURNAL OF CANCER |
| 2021 | A phase II study of poziotinib in patients with recurrent and/or metastatic head and neck squamous cell carcinoma
| CANCER MEDICINE |
| 2021 | Analyses of CNS Response to Osimertinib in Patients with T790M-Positive Advanced NSCLC from ASTRIS Korean Subset, Open-Label Real-World Study
| CANCERS |
| 2021 | Genetic Analysis and Operative Outcomes in Patients with Oncogene-Driven Advanced NSCLC Treated with Cytoreductive Surgery as a Component of Local Consolidative Therapy
| CANCERS |
| 2021 | Distinct Characteristics and Clinical Outcomes to Predict the Emergence of MET Amplification in Patients with Non-Small Cell Lung Cancer Who Developed Resistance after Treatment with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
| CANCERS |
| 2021 | Blocking TIM-3 in Treatment-refractory Advanced Solid Tumors: A Phase Ia/b Study of LY3321367 with or without an Anti-PD-L1 Antibody | CLINICAL CANCER RESEARCH |
| 2021 | Intracranial failure after hippocampal-avoidance prophylactic cranial irradiation in limited-stage small-cell lung cancer patients
| SCIENTIFIC REPORTS |
| 2021 | Overexpression of PVR and PD-L1 and its association with prognosis in surgically resected squamous cell lung carcinoma
| SCIENTIFIC REPORTS |
| 2021 | Treatment Patterns and Clinical Outcomes in Korean Cancer Patients With Venous Thromboembolism: A Retrospective Cohort Study | CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS |
| 2021 | Dynamic changes in circulating PD-1(+)CD8(+)T lymphocytes for predicting treatment response to PD-1 blockade in patients with non-small-cell lung cancer | EUROPEAN JOURNAL OF CANCER |
| 2020 | Mouse-human co-clinical trials demonstrate superior anti-tumour effects of buparlisib (BKM120) and cetuximab combination in squamous cell carcinoma of head and neck
| BRITISH JOURNAL OF CANCER |
| 2020 | The feasibility and safety of radical esophagectomy in patients receiving neoadjuvant chemoradiotherapy with pembrolizumab for esophageal squamous cell carcinoma
| JOURNAL OF THORACIC DISEASE |
| 2020 | Phase 2 study of afatinib among patients with recurrent and/or metastatic esophageal squamous cell carcinoma | CANCER |
| 2020 | Genome-wide identification of differentially methylated promoters and enhancers associated with response to anti-PD-1 therapy in non-small cell lung cancer | EXPERIMENTAL AND MOLECULAR MEDICINE |
| 2020 | Recurrent Sympathetic Ophthalmia with Annular Choroidal Detachment after Pembrolizumab Treatment: A Case Report | OCULAR IMMUNOLOGY AND INFLAMMATION |
| 2020 | Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR-MET Bispecific Antibody, in Diverse Models of EGFR Exon 20 Insertion-Driven NSCLC | CANCER DISCOVERY |
| 2020 | Comprehensive analyses of immunodynamics and immunoreactivity in response to treatment in ALK-positive non-small-cell lung cancer
| JOURNAL FOR IMMUNOTHERAPY OF CANCER |
| 2020 | Repotrectinib Exhibits Potent Antitumor Activity in Treatment-Naïve and Solvent-Front-Mutant ROS1-Rearranged Non-Small Cell Lung Cancer
| CLINICAL CANCER RESEARCH |
| 2020 | Peripheral natural killer cells and myeloid-derived suppressor cells correlate with anti-PD-1 responses in non-small cell lung cancer
| SCIENTIFIC REPORTS |
| 2020 | Molecular subtypes of oropharyngeal cancer show distinct immune microenvironment related with immune checkpoint blockade response
| BRITISH JOURNAL OF CANCER |
| 2020 | Establishment and characterization of patient-derived xenografts as paraclinical models for head and neck cancer
| BMC CANCER |
| 2020 | Immunotherapy for Non-small Cell Lung Cancer: Current Landscape and Future Perspectives
| IMMUNE NETWORK |
| 2019 | Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1-2 study | LANCET ONCOLOGY |
| 2019 | Incidence, inhospital mortality, and readmission among patients with alcoholic hepatitis in Korea: A nationwide study | Gastroenterology & Hepatology |
| 2019 | Targeting YAP to overcome acquired resistance to ALK inhibitors in ALK-rearranged lung cancer
| EMBO MOLECULAR MEDICINE |
| 2019 | Molecular characterization of lung adenocarcinoma from Korean patients using next generation sequencing
| PLOS ONE |
| 2019 | Patient-Derived Cells to Guide Targeted Therapy for Advanced Lung Adenocarcinoma
| SCIENTIFIC REPORTS |
| 2019 | High CD3 and ICOS and low TIM-3 expression predict favourable survival in resected oesophageal squamous cell carcinoma
| SCIENTIFIC REPORTS |
| 2019 | Impact of Treatment-Related Lymphopenia on Immunotherapy for Advanced Non-Small Cell Lung Cancer | INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS |
| 2019 | Dynamic changes in PD-L1 expression and CD8+ T cell infiltration in non-small cell lung cancer following chemoradiation therapy | LUNG CANCER |
| 2019 | Hyperprogressive disease during PD-1/PD-L1 blockade in patients with non-small-cell lung cancer | Annals of Oncology |
| 2019 | Predictive factors for the development of diabetes in cancer patients treated with phosphatidylinositol 3-kinase inhibitors | Cancer Chemotherapy and Pharmacology |
| 2019 | A phase Ib study of the combination of afatinib and ruxolitinib in EGFR mutant NSCLC with progression on EGFR-TKIs | Lung Cancer |
| 2019 | Comprehensive analysis of the characteristics and treatment outcomes of patients with non-small cell lung cancer treated with anti-PD-1 therapy in real-world practice
| JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY |
| 2019 | YH25448, an Irreversible EGFR-TKI with Potent Intracranial Activity in EGFR Mutant Non-Small Cell Lung Cancer | CLINICAL CANCER RESEARCH |
| 2019 | Indoor radon exposure increases tumor mutation burden in never-smoker patients with lung adenocarcinoma | LUNG CANCER |
| 2019 | Real-World Analysis of the Efficacy of Rebiopsy and EGFR Mutation Test of Tissue and Plasma Samples in Drug-Resistant Non-Small Cell Lung Cancer
| YONSEI MEDICAL JOURNAL |
| 2019 | Neoadjuvant therapy for thymic neoplasms reduces tumor volume per 3D-reconstructed images but does not improve the complete resection rate | PLOS ONE |
| 2018 | ERK-dependent IL-6 autocrine signaling mediates adaptive resistance to pan-PI3K inhibitor BKM120 in head and neck squamous cell carcinoma | ONCOGENE |
| 2018 | Characteristics and Outcome of ROS1-Positive Non-Small Cell Lung Cancer Patients in Routine Clinical Practice | JOURNAL OF THORACIC ONCOLOGY |
| 2018 | Enhancer Remodeling and MicroRNA Alterations Are Associated with Acquired Resistance to ALK Inhibitors. | CANCER RESEARCH |
http://orcid.org/0000-0003-3490-2195
(57191958755)
